THE DEBT THAT DOES NOT WAIT: Why Longevity's Race to the Bottom Outpaces AI's Own, and Why Three Named Actors Now Hold Both Ends of the Pipe

Erman and Furendal's race-to-the-bottom mechanism explains why national AI regulation underperforms relative to global coordination: a developer can withhold products from a strict jurisdiction or relocate, and jurisdictions compete downward to retain the resulting investment. No New Actor to Name applies this mechanism to longevity governance and finds Dubai's Longevity Authority advertising exactly the compliance-attracting posture the mechanism predicts. This paper argues the transfer understates its own case. The cost a sovereign regulator imposes on its population by delaying is not the same kind of cost in the two domains, and the difference is not one of degree. A jurisdiction that regulates AI conservatively and later liberalizes recovers most of the foregone value: the model still exists, still improves, and a citizen who waited two years for legal access to a since-matured system loses convenience, not biology. A jurisdiction that regulates a longevity intervention conservatively does not recover the foregone value when it later liberalizes, because the Biological Zero-Day Mechanism this corpus has already formalized reclassifies each discovery, on its date of discovery, as a preventable cause of death for everyone who could have accessed it — and a citizen who dies during the delay does not receive the intervention retroactively when the delay ends. The regulator is not merely tempted to compete downward, as Erman and Furendal's AI-governance case describes. It is squeezed from two directions at once: by capital threatening exit, in the mechanism their own work identifies, and by its own citizens, watching a comparison the Reform Acceleration Paradox this corpus's companion paper The Ledger Breaks First already shows converts patient waiting into political grievance the moment a faster jurisdiction becomes visible. No comparable second pressure operates on an AI regulator, because no comparable population is dying, specifically and namably, of the AI product's absence. A second finding follows from the first. The Asset and the Axiom, this corpus's dialogue with Dal Maso's account of longevity capitalism, establishes that the arrival rate of Biological Zero-Day Mechanism reclassification events, λ, and the diffusion rate at which an intervention reaches the population once discovered, μ, have historically been governed by different, non-overlapping classes of actor: λ by the research-infrastructure apparatus this corpus's Research Horizon Gap paper examines, largely independent of capital; μ by the capital markets and pharmaceutical firms Dal Maso's own financial instruments price. This paper shows that for the three actors No New Actor to Name identifies by name — OpenAI through Retro Biosciences and GPT-4b micro, Anthropic through Coefficient Bio and Claude Science, and Alphabet through Calico and Isomorphic Labs — this separation has collapsed. Each actor now holds first-party, simultaneous control over both the tool that sets the pace of discovery and the capital that sets the pace of delivery, a configuration this paper names Dual-Rate Capture and for which it finds no precedent in the prior history of pharmaceutical research. The paper closes by stating precisely what this configuration does and does not predict, and by naming the conditions under which each of its two claims would be falsified.